Item 2.01 Completion of Acquisition or Disposition of Assets.
On
This Current Report on Form 8-K/A amends the Initial Report to include the
following historical financial statements and pro forma financial information
required by Item 9.01 of Form 8-K that were previously omitted from the Initial
Report as permitted by Item 9.01(a)(4): (a) the audited consolidated balance
sheets of Immunomedics as of
The pro forma financial information included in this Current Report on Form 8-K/A has been presented for informational purposes only and is not necessarily indicative of the combined financial position or results of operations that would have been realized had the acquisition of Immunomedics occurred as of the dates indicated, nor is it meant to be indicative of any anticipated combined financial position or future results of operations that Gilead will experience after the acquisition.
Item 9.01 Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired.
The historical audited consolidated balance sheets of Immunomedics as of
The unaudited condensed consolidated financial statements of Immunomedics as of
(b) Pro Forma Financial Information.
The unaudited pro forma condensed combined financial information of Gilead,
giving effect to the acquisition of Immunomedics, which includes the unaudited
pro forma condensed combined balance sheet as of
(c) Exhibits Exhibit Description Number 23.1 Consent ofKPMG LLP , independent registered public accounting firm of Immunomedics. 99.1 The historical audited consolidated balance sheets of Immunomedics as ofDecember 31, 2019 and 2018, the related consolidated statement of comprehensive loss, changes in stockholders' equity and cash flows for the year endedDecember 31, 2019 , the six-month transition period endedDecember 31, 2018 , and each of the years in the two-year period endedJune 30, 2018 , the related notes and the related report ofKPMG LLP , independent registered public accounting firm of Immunomedics thereon (incorporated by reference to Immunomedics' Annual Report on Form 10-K (File No. 000-12104) for the year endedDecember 31, 2019 , as filed with theSEC onFebruary 27, 2020 ). 99.2 The unaudited condensed consolidated financial statements of Immunomedics as ofJune 30, 2020 and for the six months endedJune 30, 2020 and 2019 and the related notes (incorporated by reference to Immunomedics' Quarterly Report on Form 10-Q (File No. 000-12104) for the six months endedJune 30, 2020 , as filed with theSEC onAugust 5, 2020 ). 99.3 The unaudited pro forma condensed combined financial information of Gilead, giving effect to the acquisition of Immunomedics, which includes the unaudited pro forma condensed combined balance sheet as ofJune 30, 2020 , the unaudited pro forma condensed combined statements of operations for the year endedDecember 31, 2019 and for the six months endedJune 30, 2020 and the related notes. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source